Could maternal stress increase the risk of developing psoriasis in the offspring?

Very few data exist on the role of prenatal stress as a risk factor for psoriasis. As reported in this issue of the BJD, the impressive findings of the study by Xiaoqin Liu et al. from Aarhus University in Denmark show that prenatal exposure to severe maternal stress increases the risk of developing psoriasis in the offsprin

Does systemic treatment of psoriasis reduce the risk of comorbidities?

In this issue of the BJD, Neil Korman has published an interesting review article presenting the evidence supporting psoriasis as a systemic disease. He also discusses new psoriasis treatment paradigms, which may potentially reduce the effects of systemic inflammation and consequently prevent or reverse comorbidities.1 Optimizing patient outcomes beyond clearing the skin, such as reducing the risk of cardiovascular diseases, is crucially relevant for our clinical practice. In this commentary, the pathogenesis behind the comorbidities and whether systemic treatment of psoriasis could reduce the risk of comorbidities by damping systemic inflammation will be discussed

Skin adverse reactions to Sars‐CoV‐2 vaccination: a relevant responsibility issue for dermatologists

Commentary on the impoertant role of dermatologists when consulted for skin reactiuon to Sars-CoV-2 vaccine

Monkeypox virus infection: what dermatologist needs to know?

ingles

Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment

ingles

The Combination of Dupilumab with Other Monoclonal Antibodies

Introduction: Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD), which could be associated with atopic and non-atopic comorbidities for which concomitant administration of targeted pharmacotherapy including monoclonal antibodies could be required. However, the safety of combining dupilumab with other monoclonal antibodies for different therapeutic indication may be debated. Methods: We conducted an extensive search in MEDLINE via PubMed for original articles published from January 1, 2017 to October 22, 2022, reporting clinical cases in whic

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

Background Chronic plaque psoriasis is associated with overweight or obesity. Anti\u2013tumour necrosis factor- \u3b1 (anti-TNF- \u3b1 ) treatments are now frequently used in psoriasis management. TNF- \u3b1 is deeply involved in body weight homeostasis, which may be affected by TNF- \u3b1 \u2013targeted therapy. Objective To investigate whether anti-TNF- \u3b1 treatments is associated with changes in body weight in patients with chronic plaque psoriasis. Methods We performed a retrospective controlled analysis comparing the variations in body weight and body mass index (BMI) in three closed cohorts of psoriatic patients during a 6-month treatment with etanercept ( N = 58), infliximab ( N = 40) or methotrexate ( N = 43). Results We observed a body weight increment of 1.5 \ub1 2.7 kg (mean \ub1 SD; P = 0.0002) and 2.5 \ub1 3.3 kg ( P = 0.004) in patients treated with etanercept and infliximab, respectively. In contrast, a non-significant change (0.6 \ub1 1.4 kg; P = 0.4) was measured in patients treated with methotrexate. The BMI increased with 0.5 \ub1 0.5 ( P = 0.01) and 0.8 \ub1 1 ( P = 0.003) points in patients treated with etanercept and infliximab, respectively, whereas it did not change (< 0.2 \ub1 0.5; P = 0.06) in patients treated with methotrexate. About one fourth of patients experienced a 4- to 10-kg weight gain. Differences in body weight variations among patients treated with anti-TNF- \u3b1 therapies and methotrexate were statistically significant ( P = 0.0005). We could not identify clinical parameters predicting this phenomenon. Conclusions Patients with psoriasis treated with long-term anti-TNF- \u3b1 therapies may manifest a body weight gain. This effect should be taken into account in the global approach to patients with psoriasis

Scholarly Tracks in Emergency Medicine

Over the past decade, some residency programs in emergency medicine (EM) have implemented scholarly tracks into their curricula. The goal of the scholarly track is to identify a niche in which each trainee focuses his or her scholarly work during residency. The object of this paper is to discuss the current use, structure, and success of resident scholarly tracks. A working group of residency program leaders who had implemented scholarly tracks into their residency programs collated their approaches, implementation, and early outcomes through a survey disseminated through the Council of Emergency Medicine Residency Directors (CORD) list-serve. At the 2009 CORD Academic Assembly, a session was held and attended by approximately 80 CORD members where the results were disseminated and discussed. The group examined the literature, discussed the successes and challenges faced during implementation and maintenance of the tracks, and developed a list of recommendations for successful incorporation of the scholarly track structure into a residency program. Our information comes from the experience at eight training programs (five 3-year and three 4-year programs), ranging from 8 to 14 residents per year. Two programs have been working with academic tracks for 8 years. Recommendations included creating clear goals and objectives for each track, matching track topics with faculty expertise, protecting time for both faculty and residents, and providing adequate mentorship for the residents. In summary, scholarly tracks encourage the trainee to develop an academic or clinical niche within EM during residency training. The benefits include increased overall resident satisfaction, increased success at obtaining faculty and fellowship positions after residency, and increased production of scholarly work. We believe that this model will also encourage increased numbers of trainees to choose careers in academic medicine.ACADEMIC EMERGENCY MEDICINE 2010; 17:S87–S94 © 2010 by the Society for Academic Emergency MedicinePeer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/79229/1/j.1553-2712.2010.00890.x.pd

Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study

Background: Psoriasis is a common, chronic, inflammatory skin disease with the majority of individuals having limited disease, treated with topical medication. However, special attributes of topical treatments like galenic/cosmetic properties or an inconvenient treatment schedule may result in low preference for topical treatments. Hence, there is strong medical need for a topical medication, which is highly efficacious, easy-to-use and preferred by both physicians and patients. Objective: Blinded interim analysis with the purpose to assess efficacy of (both from the physician's and patient's perspective) and the patients' preference with a highly efficacious and easy-to-use fixed combination of calcipotriol/betamethasone dipropionate topical gel after 8 weeks of once daily treatment in a large patient population. Methods: In this phase IV, international, multicentre, randomized, controlled, prospective, parallel group study, adult patients with active, mild to moderate psoriasis despite previous topical psoriasis treatment, i.e. unsuccessful in the 8 weeks preceding study participation, are followed over 64 weeks. During the first 8 weeks the patients apply their medication once a day followed by a 56-weeks maintenance period according to SmPC. Blinded interim analysis of all patients included demographics, Physician's Global Assessment, the novel Patient's self Global Assessment (PsGA) and Patient Preference Questionnaire (PPQ). Results: 1795 patients were analysed. At week 8, 36.5% of the physicians rated the patients' psoriasis as clear/almost clear. Similarly, based on the patients' self-assessment, 34.2% had a clear/almost clear score of PsGA in week 8. Analysis of the PPQ showed that the vast majority of the patients judged their 8-week treatment to be preferable compared with their previous treatments. Conclusion: Results of this blinded interim analysis indicate that the fixed combination of calcipotriol/betamethasone dipropionate gel is highly efficacious and preferred by the majority of analysed patients

Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis

Erythrodermic psoriasis (EP) is one of the most severe cutaneous conditions which may lead to serious morbidity and even mortality. This condition is often difficult to manage and, due to its rarity (estimated prevalence 1–2.25% of psoriatic patients) there is a lack of high-quality medical literature examining treatment options [1]